Trial Profile

A phase 1 trial of MST-0300 in solid tumor patients

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 30 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs M 300 (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Mestag Therapeutics

Most Recent Events

30 Aug 2024 New trial record
28 Aug 2024 According to a Mestag Therapeutics media release, company today has been awarded a ''Transforming Cancer Therapeutics'' grant from Innovate UK's Cancer Therapeutics program ($1.9 million). This UK funding will enable to advance MST-0300 rapidly to solid tumor patients who urgently need new treatment options.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com